New Drug for Pediatric Neuroblastoma Shows Promise in Preclinical StudiesPosted: December 17, 2015
An international research team has identified a possible new treatment target for pediatric neuroblastoma and is planning an early-stage clinical trial of a drug that inhibits this target.
Monoclonal Antibody Therapy for Relapsed or Treatment-Resistant NeuroblastomaPosted: September 9, 2014
NCI is sponsoring two clinical trials of a monoclonal antibody called ch14.18, in combination with other drugs, to see if the antibody may be helpful for children or young adults (up to age 21) with relapsed or refractory high-risk neuroblastoma.
Drug used in NIH-supported trial shows benefit in children with previously treated cancersPosted: May 16, 2012
Young patients with some types of advanced cancer, for whom standard treatment had failed, had their tumors disappear during treatment with a drug that both targets and blocks a protein associated with their disease. These findings are from a Phase I, multicenter trial, led by investigators from the Children's Oncology Group (COG), and supported by the National Cancer Institute (NCI), part of the National Institutes of Health.